Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Stomach Neoplasms 135Pancreatic Neoplasms 36Esophageal Neoplasms 19Biliary Tract Neoplasms 19Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 12Neoplasm Metastasis 10Cholangiocarcinoma 8Carcinoma, Non-Small-Cell Lung 7Gastrointestinal Neoplasms 6Nasopharyngeal Carcinoma 5Colonic Neoplasms 5Adenocarcinoma 5Recurrence 4Neoplasms 4Head and Neck Neoplasms 4Advanced Pancreatic Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Gastric Adenocarcinoma 3Gallbladder Neoplasms 3Advanced Solid Tumors 3Stage IV Gastric Cancer With Metastasis 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2NSCLC 2Locally Advanced Pancreatic Cancer 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2

Interventions

Gastrectomy 4apatinib 3Taxes 3S 1 (combination) 3Oxaliplatin 3Cisplatin 3sintilimab 2Paclitaxel 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2Albumin-Bound Paclitaxel 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tipiracil 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1andecaliximab 1XELOX 1Trifluridine 1Tegafur 1Tadalafil 1SHR-1701 1Resistance Training 1Radiotherapy 1Platinum 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Gastric Adenocarcinoma × S 1 (combination) × Clear all
NCT07464756 2026-03-11

SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Gastric Adenocarcinoma

NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT01283217 2013-06-04

Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer

Yonsei University

Phase 3 Unknown
166 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡